-
1
The study evaluates the diagnostic utility of 18F-FDG PET/CT for predicting pathological response in non-small cell lung cancer after neoadjuvant therapy.
-
2
Fourteen studies with 1,315 subjects were analyzed, revealing high predictive accuracy for major pathological response using metabolic parameters.
-
3
The metabolic parameter ΔSUVmax% achieved an sAUC of 0.96, with sensitivity of 0.87 and specificity of 0.93 for predicting major pathological response.
-
4
The parameter SUVmax also demonstrated strong predictive performance, with an sAUC of 0.95, sensitivity of 0.80, and specificity of 0.94.
-
5
Quantitative metrics from 18F-FDG PET/CT may enhance individualized treatment strategies, but further high-quality research is needed to confirm these findings.
